open access

https://hdl.handle.net/2115/79577

Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer

英語

therapeutic drug monitoring

2020-05

The Pharmaceutical Society of Japan （日本薬学会）

Biological & pharmaceutical bulletin

43(5)

762-766

The currently approved dose of pazopanib (800mg) is being re-examined owing to its adverse effects. The aim of this study was to evaluate the relationships among starting or maintenance doses of pazopanib, estimated pazopanib C-min, and other clinical factors, including albumin and a-1 acid glycoprotein levels, in soft-tissue sarcoma and renal cell carcinoma. We also determined whether therapeutic drug monitoring of pazopanib concentrations may be used to improve its therapeutic efficacy and prevent adverse effects. Forty patients who received pazopanib for renal cancer or soft-tissue sarcoma at the Hokkaido Cancer Center were evaluated prospectively. C-min, for pazopanib was calculated based on the measured values from the plasma samples. The efficacy and time to treatment failure were then assessed. The pazopanib maintenance doses were 200 (n=4), 400 (n=34), 600 (n=4), and 800mg (m = 1). Most patients (65%) who received a 400 mg dose had an effective pazopanib concentration (>= 20//g/mL), whereas 35% of patients who received the 400mg dose had ineffective concentrations (<20 mu g/mL). Logistic regression analysis revealed that only the albumin level was significantly associated with effective pazopanib concentrations (odds ratio: 1.37, p= 0.0234). In conclusion, a dose of 400mg had been effective and well tolerated in more than half of patients in this study. However, therapeutic drug monitoring is necessary during pazopanib therapy.

学術雑誌論文

Version of Record

0918-6158